Fundz

Alchemab Therapeutics raised an undisclosed amount in Series A extension financing, led by Ono Venture Investment along with existing investors. The funding will advance ATLX-2847 into clinical development.

PRIVATESep 09, 2025

Round Type

Series A

LondonBiotechnologyHealth CareTherapeuticsPharmaceutical

Investors

LillyOno Venture InvestmentRA CapitalSV Health InvestorsDCVC BioLightstone Ventures

Description

Alchemab Therapeutics, a London-based biopharmaceutical company, raised an undisclosed amount in Series A extension funding. The company intends to use the funds to advance ATLX-2847, a program for muscle atrophy, into clinical development. Backers included Ono Venture Investment and existing investors RA Capital, SV Health Investors, DCVC Bio, and Lightstone Ventures. The total amount raised to date is $114M.

Who to call at Alchemab Therapeutics, and when

A new round usually means Alchemab Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Alchemab Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Alchemab Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Alchemab Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Alchemab Therapeutics

Location

London, England, United Kingdom

About

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Alchemab Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

5 contacts
Verified contactsJorge D., Director Antibody Discovery hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Alchemab Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Alchemab Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.